Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucagon, Glucose Monitoring Mar 11 | 2021Zealand Q4 '20 Earnings Update; Nemaura Submits for sugarBEAT Reimbursement in GermanyPurchase Blast
$599
Posted in: SGLT2i Mar 10 | 2021Lexicon Confident in Sota HF Label After Entresto Approval; Lexicon Q4 and FY '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Other Mar 10 | 2021Lannett Receives FDA Feedback for Bs-glargine; Adocia Initiates Ph2 M1Pram Trial; Vertex Receives Fast Track Designation for VX-880 in T1DM; Welldoc Hires New CMO; Intercept CFO to DepartPurchase Blast
$599
Posted in: Glucagon, Other Mar 09 | 2021Xeris and Dario Q4 and FY '20 Earnings Calls; Lilly Research Collaboration for Diabetes; Metacrine Initiates Ph2a Trial in NASHPurchase Blast
$599
Posted in: Dual/triple agonist, Glucagon, Other Mar 05 | 2021Zealand R&D Day HighlightsPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 04 | 2021Senseonics Q4 '20 Earnings Update; Provention Bio Extended Follow-up Data Published; Voluntis Collaborates with Zendesk for Global Customer SupportPurchase Blast
$599
Posted in: Dual/triple agonist Mar 04 | 2021Payback for Lilly as Tirzepatide Beats Ozempic in Ph3 SURPASS-2 H2H TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Mar 01 | 2021BI and Gubra Partner for Obesity Drug Development; Diabeloop DBLG1 Integrates with Accu-Chek Insight Pump; Tandem Appoints Jordan Pinsker as VP and Medical DirectorPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Mar 01 | 2021Viatris Generic Rybelsus in the Pipeline; Viatris 2021 Investor DayPurchase Blast
$599
Posted in: Other, SGLT2i Feb 26 | 2021Thoughts on Sotagliflozin HF Indication after Entresto's PARAGON ApprovalPurchase Blast
$599
Posted in: Bolus Insulin, GLP-1RA, Other Feb 25 | 2021Novo Invests in Danish Facility for Oral Sema Production; MNKD, PRVB, ICPT, BAYRY, and IONS Q4 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery Feb 25 | 2021Lilly Partners with Welldoc for Connected Pen AppPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 24 | 2021Tandem and Teladoc Q4 and FY '20 Earnings UpdatesPurchase Blast
$599
Posted in: Insulin Delivery, Other Feb 23 | 2021Insulet and Esperion Q4 '20 Earnings UpdatesPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 23 | 2021Medtronic CY Q4 '20 (FY Q3 '21) Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, SGLT2i Feb 22 | 2021DAPA-CKD filed with EMA; February 22-25 CHMP Agenda; G&L Partners with IDFPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Feb 18 | 2021Biocorp Partners with Health2Sync and SocialDiabetes for Connected Pen IntegrationPurchase Blast
$599
Posted in: Dual/triple agonist Feb 17 | 2021Tirzepatide Continues to Perform; Positive Ph3 SURPASS-3 and SURPASS-5 Topline ResultsPurchase Blast
$599
Posted in: Other Feb 16 | 2021Novartis Wins with Entresto PARAGON-HF FDA ApprovalPurchase Blast